These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 18643796)

  • 1. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.
    Hill MN; Carrier EJ; McLaughlin RJ; Morrish AC; Meier SE; Hillard CJ; Gorzalka BB
    J Neurochem; 2008 Sep; 106(6):2322-36. PubMed ID: 18643796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity.
    Hill MN; Barr AM; Ho WS; Carrier EJ; Gorzalka BB; Hillard CJ
    J Neurochem; 2007 Oct; 103(1):47-56. PubMed ID: 17561935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents.
    Hill MN; Ho WS; Hillard CJ; Gorzalka BB
    J Neural Transm (Vienna); 2008 Dec; 115(12):1673-9. PubMed ID: 18974922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis.
    Hill MN; Ho WS; Sinopoli KJ; Viau V; Hillard CJ; Gorzalka BB
    Neuropsychopharmacology; 2006 Dec; 31(12):2591-9. PubMed ID: 16710317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
    Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
    Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis.
    Hill MN; McLaughlin RJ; Morrish AC; Viau V; Floresco SB; Hillard CJ; Gorzalka BB
    Neuropsychopharmacology; 2009 Dec; 34(13):2733-45. PubMed ID: 19710634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus.
    Hill MN; Carrier EJ; Ho WS; Shi L; Patel S; Gorzalka BB; Hillard CJ
    Hippocampus; 2008; 18(2):221-6. PubMed ID: 18058925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiency in endocannabinoid signaling in the nucleus accumbens induced by chronic unpredictable stress.
    Wang W; Sun D; Pan B; Roberts CJ; Sun X; Hillard CJ; Liu QS
    Neuropsychopharmacology; 2010 Oct; 35(11):2249-61. PubMed ID: 20664582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoids in the treatment of mood disorders: evidence from animal models.
    Bambico FR; Duranti A; Tontini A; Tarzia G; Gobbi G
    Curr Pharm Des; 2009; 15(14):1623-46. PubMed ID: 19442178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets.
    Bambico FR; Gobbi G
    Expert Opin Ther Targets; 2008 Nov; 12(11):1347-66. PubMed ID: 18851692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect.
    McLaughlin RJ; Hill MN; Morrish AC; Gorzalka BB
    Behav Pharmacol; 2007 Sep; 18(5-6):431-8. PubMed ID: 17762511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of CB₁ receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure.
    McLaughlin RJ; Hill MN; Dang SS; Wainwright SR; Galea LA; Hillard CJ; Gorzalka BB
    Behav Brain Res; 2013 Jan; 237():333-7. PubMed ID: 23047058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoid modulation of male rat sexual behavior.
    Gorzalka BB; Morrish AC; Hill MN
    Psychopharmacology (Berl); 2008 Jul; 198(4):479-86. PubMed ID: 17694389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats.
    Vinod KY; Xie S; Psychoyos D; Hungund BL; Cooper TB; Tejani-Butt SM
    PLoS One; 2012; 7(5):e36743. PubMed ID: 22606285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system.
    Vinod KY; Yalamanchili R; Xie S; Cooper TB; Hungund BL
    Neurochem Int; 2006 Nov; 49(6):619-25. PubMed ID: 16822589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.
    Mitchell VA; Greenwood R; Jayamanne A; Vaughan CW
    Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1186-90. PubMed ID: 17880375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice.
    Bowles NP; Hill MN; Bhagat SM; Karatsoreos IN; Hillard CJ; McEwen BS
    Neuroscience; 2012 Mar; 204():83-9. PubMed ID: 21939741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anxiolytic-like properties of the anandamide transport inhibitor AM404.
    Bortolato M; Campolongo P; Mangieri RA; Scattoni ML; Frau R; Trezza V; La Rana G; Russo R; Calignano A; Gessa GL; Cuomo V; Piomelli D
    Neuropsychopharmacology; 2006 Dec; 31(12):2652-9. PubMed ID: 16541083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.